{
  "source": "PA-Med-Nec-Vivjoa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2284-3\nProgram Prior Authorization/Medical Necessity\nMedication Vivjoa® (oteseconazole)\nP&T Approval Date 8/2022, 8/2023, 8/2024\nEffective Date 11/1/2024\n1. Background:\nVivjoa (oteseconazole) is an azole antifungal indicated to reduce the incidence of recurrent\nvulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of\nreproductive potential.\n2. Coverage Criteriaa:\nA. Authorization\n1. Vivjoa will be approved based on all of the following criteria:\na. Diagnosis of recurrent vulvovaginal candidiasis\n-AND-\nb. Patient is not of reproductive potential (i.e., persons who are biological females who\nare postmenopausal or have another reason for permanent infertility [(e.g., tubal\nligation, hysterectomy, salpingo-oophorectomy)]\n-AND-\nc. Both of the following:\n1) Other causes (including but not limited to bacterial vaginosis or trichomoniasis)\nhave been ruled out\n-AND-\n2) Failure of a maintenance course of oral fluconazole defined as 100-mg, 150-mg,\nor 200-mg taken weekly for 6 monthsb.\n-AND-\nd. Prescribed by or in consultation with one of the following:\n1) Infectious disease physician\n2) Obstetrician/Gynecologist\nAuthorization will be issued for 4 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business, only a 30-day trial will be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Step Therapy may be in place\n4. References:\n1. Vivjoa [package insert]. Durham",
    "10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Step Therapy may be in place\n4. References:\n1. Vivjoa [package insert]. Durham, NC: Mycovia Pharmaceuticals, Inc; April 2022.\n2. Sexually Transmitted Infections Treatment Guidelines, 2021. Vulvovaginal Candidiasis\n(VVC). Centers for Disease Control and Prevention. https://www.cdc.gov/std/treatment-\nguidelines/candidiasis.htm. Accessed July 2024..\nProgram Prior Authorization/Medical Necessity - Vivjoa\nChange Control\n8/2022 New program.\n8/2023 Annual review. No changes.\n8/2024 Annual review. Updated regulatory statement.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}